5.75 USD
-0.13
2.21%
At close May 15, 4:00 PM EDT
After hours
5.75
+0.00
0.00%
1 day
-2.21%
5 days
-9.31%
1 month
-20.14%
3 months
-45.70%
6 months
-42.79%
Year to date
-37.43%
1 year
-34.95%
5 years
-84.72%
10 years
-85.08%
 

About: Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

Employees: 766

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

115% more call options, than puts

Call options by funds: $2.11M | Put options by funds: $979K

67% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 30

20% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 20

1% more funds holding

Funds holding: 133 [Q3] → 134 (+1) [Q4]

1.37% less ownership

Funds ownership: 85.45% [Q3] → 84.08% (-1.37%) [Q4]

7% less capital invested

Capital invested by funds: $197M [Q3] → $184M (-$12.9M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$7
22%
upside
Avg. target
$7
22%
upside
High target
$7
22%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Stifel
Mathew Blackman
44% 1-year accuracy
7 / 16 met price target
22%upside
$7
Hold
Maintained
8 May 2025

Financial journalist opinion

Based on 7 articles about INGN published over the past 30 days

Positive
Zacks Investment Research
1 week ago
INGN Stock Gains Following Q1 Earnings Beat, Revenues Up Y/Y
Inogen's overall first-quarter 2025 results continue to gain from higher business-to-business sales.
INGN Stock Gains Following Q1 Earnings Beat, Revenues Up Y/Y
Neutral
Seeking Alpha
1 week ago
Inogen, Inc. (INGN) Q1 2025 Earnings Call Transcript
Inogen, Inc. (NASDAQ:INGN ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Ryan Peterson - Investor Relations Kevin Smith - President and CEO Mike Bourque - CFO Conference Call Participants Colin Clark - Stifel Mike Matteson - Needham & Company Margaret Andrew - William Blair Operator Welcome to Inogen's First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Inogen, Inc. (INGN) Q1 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 week ago
Here's What Key Metrics Tell Us About Inogen (INGN) Q1 Earnings
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Here's What Key Metrics Tell Us About Inogen (INGN) Q1 Earnings
Negative
Zacks Investment Research
1 week ago
Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates
Inogen (INGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.62 per share a year ago.
Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates
Neutral
Business Wire
1 week ago
Inogen Announces First Quarter 2025 Financial Results
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces First Quarter 2025 Financial Results.
Inogen Announces First Quarter 2025 Financial Results
Neutral
Zacks Investment Research
1 week ago
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN
The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tariffs, inflationary costs, and supply chain disruptions continued to pressure margins.
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN
Positive
Zacks Investment Research
4 weeks ago
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Neutral
Business Wire
1 month ago
Inogen To Present at 24th Annual Needham Virtual Healthcare Conference
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen To Present at 24th Annual Needham Virtual Healthcare Conference.
Inogen To Present at 24th Annual Needham Virtual Healthcare Conference
Positive
Zacks Investment Research
2 months ago
Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Positive
Zacks Investment Research
2 months ago
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Inogen, Inc.  INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid fourth-quarter 2024 performance and a strong product portfolio, seems justified.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Charts implemented using Lightweight Charts™